POLIO
MCID: PLM031
MIFTS: 64

Poliomyelitis (POLIO)

Categories: Infectious diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Poliomyelitis

MalaCards integrated aliases for Poliomyelitis:

Name: Poliomyelitis 12 74 52 58 43 15 17 71
Infantile Paralysis 52 71
Polio 52 54

Characteristics:

Orphanet epidemiological data:

58
poliomyelitis
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Childhood; Age of death: any age;

Classifications:

Orphanet: 58  
Rare neurological diseases


Summaries for Poliomyelitis

NIH Rare Diseases : 52 Poliomyelitis is a viral disease that can affect nerves and can lead to partial or full paralysis . It is caused by infection with the poliovirus which can be spread by direct person-to-person contact, by contact with infected mucus or phlegm from the nose or mouth, or by contact with infected feces. There are three basic patterns of polio infection: subclinical infections, nonparalytic, and paralytic. Symptoms vary based on the pattern of infection and can range from asymptomatic with subclinical poliomyelitis to partial or full paralysis. Treatment is aimed at controlling symptoms while the infection runs its course. Since the development of the polio vaccine, the incidence of the disease has been greatly reduced. The prognosis depends on the form of the disease (subclinical, nonparalytic, or paralytic) and the site affected.

MalaCards based summary : Poliomyelitis, also known as infantile paralysis, is related to paralytic poliomyelitis and diphtheria. An important gene associated with Poliomyelitis is PVR (PVR Cell Adhesion Molecule), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Zinc and Edetic Acid have been mentioned in the context of this disorder. Affiliated tissues include testes, spinal cord and brain, and related phenotypes are vomiting and fatigue

Disease Ontology : 12 A viral infectious disease that results in destruction located in motor neurons, has material basis in Human poliovirus 1, has material basis in Human poliovirus 2, or has material basis in Human poliovirus 3, which are transmitted by ingestion of food or water contaminated with feces, or transmitted by direct contact with the oral secretions. The infection has symptom fever, has symptom sore throat, has symptom headache, has symptom vomiting, has symptom fatigue, has symptom neck stiffness, has symptom muscle spasms, and has symptom acute flaccid paralysis.

Wikipedia : 74 Polio, short for poliomyelitis, is an infectious disease caused by the poliovirus. In about 0.5 percent... more...

Related Diseases for Poliomyelitis

Diseases related to Poliomyelitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 726)
# Related Disease Score Top Affiliating Genes
1 paralytic poliomyelitis 33.4 RASA3 PVR KHSRP EVC CD40LG BTK
2 diphtheria 31.7 TNF IL4 IFNG CD40LG
3 tetanus 31.6 TNF IL4 IL10 IFNG CD40LG
4 encephalitis 31.5 TNF IL4 IL10 CD40LG
5 smallpox 31.3 TNF IL4 IFNG ICAM1
6 myelitis 31.2 TNF IL10 CD40LG
7 mumps 31.1 TNF IL10 IFNG CD40LG
8 neuritis 31.1 TNF IL4 IL10 IFNG
9 rubella 30.9 TNF IL4 IL10 IFNG CD40LG
10 hand, foot and mouth disease 30.9 SCARB2 IL10 IFNG
11 dermatitis 30.7 TNF IL4 IL10 IFNG
12 viral encephalitis 30.7 TNF IL10 CD40LG
13 sleep apnea 30.7 TNF LEP IL10 ICAM1
14 meningoencephalitis 30.7 TNF IL4 IL10 CD40LG
15 myocarditis 30.7 TNF IL4 IL10 IFNG ICAM1 CD40LG
16 graft-versus-host disease 30.6 TNF IL10 IFNG
17 multiple sclerosis 30.6 TNF IL4 IL10 IFNG ICAM1 CD40LG
18 penicillin allergy 30.6 IL4 IL10 IFNG
19 hepatitis a 30.6 TNF IL4 IL10 IFNG
20 osteomyelitis 30.6 TNF IL4 IL10 IFNG
21 cerebral palsy 30.5 TNF LEP IL4 IL10
22 complex regional pain syndrome 30.5 TNF IL10 IFNG
23 acute hemorrhagic conjunctivitis 30.5 SCARB2 PVR ICAM1 EVC
24 chickenpox 30.5 TNF IL4 IL10 IFNG CD40LG
25 typhoid fever 30.5 TNF IFNG CD40LG
26 syphilis 30.5 TNF IFNG CD40LG
27 arthritis 30.5 TNF IL4 IL10 IFNG ICAM1
28 aseptic meningitis 30.5 TNF SCARB2 IL10 IFNG EVC CD40LG
29 spondylitis 30.5 TNF IL10 IFNG
30 conjunctivitis 30.4 TNF IL4 IL10 IFNG ICAM1 BTK
31 exanthem 30.4 TNF IL10 IFNG CD40LG
32 meningitis 30.4 TNF IL4 IL10 IFNG ICAM1 FCGR2A
33 bacterial meningitis 30.4 TNF IL10 IFNG
34 transient hypogammaglobulinemia 30.3 TNF IL10 CD40LG
35 myasthenia gravis 30.3 TNF IL4 IL10 IFNG CD40LG
36 mycobacterium tuberculosis 1 30.3 TNF IL4 IL10 IFNG
37 pyelonephritis 30.3 TNF IL10 IFNG
38 acquired immunodeficiency syndrome 30.3 TNF IL10 IFNG ICAM1 FCGR3A CD40LG
39 pulmonary edema 30.3 TNF IL10 ICAM1
40 appendicitis 30.3 TNF IL10 IFNG
41 arteriosclerosis 30.3 IL4 IL10 IFNG ICAM1
42 allergic hypersensitivity disease 30.3 TNF IL4 IL10 IFNG ICAM1
43 agammaglobulinemia, x-linked 30.3 IL4 CD40LG BTK
44 thrombocytopenia due to platelet alloimmunization 30.2 IL10 FCGR2A CD40LG
45 chlamydia pneumonia 30.2 TNF IL10 CD40LG
46 pneumonia 30.2 TNF IL4 IL10 IFNG ICAM1 CD40LG
47 trichinosis 30.2 IL4 IL10 CD40LG
48 reactive arthritis 30.2 TNF IL10 IFNG
49 chronic fatigue syndrome 30.2 TNF LEP IL4 IL10 IFNG
50 common cold 30.2 TNF IL4 IL10 ICAM1

Graphical network of the top 20 diseases related to Poliomyelitis:



Diseases related to Poliomyelitis

Symptoms & Phenotypes for Poliomyelitis

Human phenotypes related to Poliomyelitis:

58 31 (show top 50) (show all 53)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002013
2 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
3 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
4 skeletal muscle atrophy 58 31 frequent (33%) Frequent (79-30%) HP:0003202
5 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
6 myalgia 58 31 frequent (33%) Frequent (79-30%) HP:0003326
7 anorexia 58 31 frequent (33%) Frequent (79-30%) HP:0002039
8 areflexia 58 31 frequent (33%) Frequent (79-30%) HP:0001284
9 meningitis 58 31 frequent (33%) Frequent (79-30%) HP:0001287
10 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
11 paralysis 58 31 frequent (33%) Frequent (79-30%) HP:0003470
12 muscle flaccidity 58 31 frequent (33%) Frequent (79-30%) HP:0010547
13 hypoplasia of the musculature 58 31 frequent (33%) Frequent (79-30%) HP:0009004
14 brisk reflexes 58 31 frequent (33%) Frequent (79-30%) HP:0001348
15 lower limb muscle weakness 58 31 frequent (33%) Frequent (79-30%) HP:0007340
16 exercise intolerance 58 31 frequent (33%) Frequent (79-30%) HP:0003546
17 nausea 58 31 frequent (33%) Frequent (79-30%) HP:0002018
18 myelitis 58 31 frequent (33%) Frequent (79-30%) HP:0012486
19 stiff neck 58 31 frequent (33%) Frequent (79-30%) HP:0025258
20 abnormal motor nerve conduction velocity 58 31 frequent (33%) Frequent (79-30%) HP:0040131
21 pharyngitis 58 31 frequent (33%) Frequent (79-30%) HP:0025439
22 low self esteem 58 31 frequent (33%) Frequent (79-30%) HP:0031469
23 cranial nerve paralysis 58 31 occasional (7.5%) Occasional (29-5%) HP:0006824
24 dysphagia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002015
25 immunodeficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0002721
26 bulbar signs 58 31 occasional (7.5%) Occasional (29-5%) HP:0002483
27 paresthesia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003401
28 dysphonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001618
29 fasciculations 58 31 occasional (7.5%) Occasional (29-5%) HP:0002380
30 respiratory failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0002878
31 respiratory failure requiring assisted ventilation 58 31 occasional (7.5%) Occasional (29-5%) HP:0004887
32 inability to walk 58 31 occasional (7.5%) Occasional (29-5%) HP:0002540
33 paraparesis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002385
34 upper limb muscle weakness 58 31 occasional (7.5%) Occasional (29-5%) HP:0003484
35 bulbar palsy 58 31 occasional (7.5%) Occasional (29-5%) HP:0001283
36 fatigable weakness of respiratory muscles 58 31 occasional (7.5%) Occasional (29-5%) HP:0030196
37 hyperkinetic movements 58 31 occasional (7.5%) Occasional (29-5%) HP:0002487
38 absent tonsils 58 31 occasional (7.5%) Occasional (29-5%) HP:0030813
39 diminished movement 58 31 occasional (7.5%) Occasional (29-5%) HP:0002374
40 impairment of activities of daily living 58 31 occasional (7.5%) Occasional (29-5%) HP:0031058
41 paralytic ileus 58 31 occasional (7.5%) Occasional (29-5%) HP:0002590
42 irritability 58 31 very rare (1%) Very rare (<4-1%) HP:0000737
43 hypertension 58 31 very rare (1%) Very rare (<4-1%) HP:0000822
44 encephalitis 58 31 very rare (1%) Very rare (<4-1%) HP:0002383
45 hypotension 58 31 very rare (1%) Very rare (<4-1%) HP:0002615
46 confusion 58 31 very rare (1%) Very rare (<4-1%) HP:0001289
47 coma 58 31 very rare (1%) Very rare (<4-1%) HP:0001259
48 agitation 58 31 very rare (1%) Very rare (<4-1%) HP:0000713
49 hypovolemic shock 58 31 very rare (1%) Very rare (<4-1%) HP:0031274
50 muscle weakness 58 Very frequent (99-80%)

MGI Mouse Phenotypes related to Poliomyelitis:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.35 ARHGEF1 ATG7 BTK CD40LG DLG1 FCGR2A
2 immune system MP:0005387 10.34 ARHGEF1 ATG7 BTK CD40LG DLG1 FCGR2A
3 cellular MP:0005384 10.33 ATG7 BTK CD40LG DLG1 EVC ICAM1
4 homeostasis/metabolism MP:0005376 10.33 ARHGEF1 ATG7 BTK CD40LG DLG1 FCGR3B
5 growth/size/body region MP:0005378 10.31 ATG7 BTK DLG1 EVC ICAM1 IFNG
6 cardiovascular system MP:0005385 10.26 ARHGEF1 ATG7 CD40LG ICAM1 IFNG IL10
7 mortality/aging MP:0010768 10.25 ARHGEF1 ATG7 BTK CD40LG DLG1 EVC
8 digestive/alimentary MP:0005381 10.18 ATG7 BTK DLG1 ICAM1 IFNG IL10
9 endocrine/exocrine gland MP:0005379 10.16 ATG7 CD40LG DLG1 ICAM1 IFNG IL10
10 integument MP:0010771 10.1 ATG7 BTK CD40LG ICAM1 IFNG IL10
11 craniofacial MP:0005382 10.08 DLG1 EVC IFNG IL10 IL4 PES1
12 limbs/digits/tail MP:0005371 9.91 ATG7 BTK DLG1 EVC IL10 LEP
13 muscle MP:0005369 9.86 ARHGEF1 ATG7 DLG1 ICAM1 IFNG IL10
14 neoplasm MP:0002006 9.7 ATG7 BTK ICAM1 IFNG IL10 LEP
15 nervous system MP:0003631 9.7 ATG7 CD40LG DLG1 ICAM1 IFNG IL10
16 skeleton MP:0005390 9.36 CD40LG DLG1 EVC FCGR2A FCGR3B IFNG

Drugs & Therapeutics for Poliomyelitis

Drugs for Poliomyelitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 133)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4 7440-66-6 32051
2
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
3
Pentetic acid Approved Phase 4 67-43-6
4
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
5
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
6
Calcium carbonate Approved, Investigational Phase 4 471-34-1
7
Inulin Approved, Investigational, Nutraceutical Phase 4 9005-80-5 24763
8
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
9
BCG vaccine Investigational Phase 4
10 Antibodies, Blocking Phase 4
11 Chelating Agents Phase 4
12 Iron Chelating Agents Phase 4
13 Acidophilus Phase 4
14 Zinc Supplement Phase 4
15 Fibrinolytic Agents Phase 4
16 Anticoagulants Phase 4
17 Hormone Antagonists Phase 4
18 Adrenocorticotropic Hormone Phase 4
19 Melanocyte-Stimulating Hormones Phase 4
20 Immunoglobulin A Phase 4
21 beta-Endorphin Phase 4
22 Hormones Phase 4
23 Retinol palmitate Phase 4
24 retinol Phase 4
25 Antibodies Phase 4
26 Immunoglobulins Phase 4
27 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
28 Chrysanthemum Phase 4
29
Sulfadoxine Approved, Investigational Phase 2, Phase 3 2447-57-6 17134
30
Pyrimethamine Approved, Investigational, Vet_approved Phase 2, Phase 3 58-14-0 4993
31
Lactitol Approved, Investigational Phase 3 585-88-6, 585-86-4 493591
32
Proguanil Approved Phase 2, Phase 3 500-92-5 4923
33
Dapsone Approved, Investigational Phase 2, Phase 3 80-08-0 2955
34
Mefloquine Approved, Investigational Phase 2, Phase 3 53230-10-7 4046
35
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
36
leucovorin Approved Phase 3 58-05-9 6006 143
37
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
38
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
39
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
40
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
41
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
42
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
43
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
44
Etoposide Approved Phase 3 33419-42-0 36462
45
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
46
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
47
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
48
Chlorproguanil Investigational Phase 2, Phase 3 537-21-3 151170 9571037
49 Calcium, Dietary Phase 3
50 taxane Phase 3

Interventional clinical trials:

(show top 50) (show all 344)
# Name Status NCT ID Phase Drugs
1 A Phase 4, Randomized, Open-Label Study to Assess Humoral and Intestinal Polio Immunity Following a Three-Dose Trivalent Inactivated Polio Vaccine Schedule Relative to Two Sequential Schedules of IPV/Bivalent Oral Polio Vaccines Unknown status NCT01841671 Phase 4
2 Safety Study of IMOVAX Polio™ in Selected Cities in China, an Observational Post Marketing Study Completed NCT01244464 Phase 4
3 Evaluation of GSK Biologicals' Boostrix™ Polio in Healthy Adults, 10 Years After a Booster Vaccination Completed NCT01323959 Phase 4
4 Large Scale Safety Study of IMOVAX Polio in Selected Cities in China, an Observational Post Marketing Study Completed NCT01278433 Phase 4
5 Immunogenicity and Safety of Different Sequential Schedules of Inactivated Poliomyelitis Vaccine (IMOVAX Polio®) Followed by Oral Poliomyelitis Vaccine in Healthy Infants in China Versus Oral Poliomyelitis Vaccine Alone. Completed NCT01475539 Phase 4
6 Immunogenicity and Safety of IMOVAX POLIO® Subcutaneous as a Booster Given in Pre-school Age Children in Japan Completed NCT02005536 Phase 4
7 Antibody Persistence in 11 to 13-year-old Children Previously Vaccinated at 6 Years Old With Either REVAXIS or DT Polio, and Immune Response to a Booster Dose of TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
8 A Phase 4 Study to Evaluate the Safety and Immunogenicity of Monovalent Oral Polio Vaccine Type 2 in Healthy IPV-vaccinated Children Aged 1 to 5 Years in Lithuania Completed NCT02582255 Phase 4
9 A Phase 4 Study to Evaluate the Safety and Immunogenicity of Trivalent Oral Polio Vaccine in Healthy Polio Vaccinated Children 1 to 5 Years of Age and in Healthy Unvaccinated Infants at 6 Weeks of Age in the Dominican Republic Completed NCT02580201 Phase 4
10 Open Clinical Study to Assess the Immune Response and Safety of a Booster Dose (5th Dose) of a Combination Vaccine Against Diphteria-Tetanus-Pertussis-Polio Given to Healthy Adolescents 15-16 Years of Age. Completed NCT00514059 Phase 4 Boostrix polio
11 Assessing Immunogenicity of Type 2 Monovalent Oral Poliovirus Vaccine Administered at One, Two or Four Week Intervals and When Coadministered With Inactivated Poliovirus Vaccine in an Urban Area in Bangladesh Completed NCT02643368 Phase 4
12 Polio End-game Strategies - Poliovirus Type 2 Challenge Study Completed NCT02189811 Phase 4
13 A Phase 4, Randomized Study to Evaluate the Safety and the Humoral and Intestinal Immunogenicity of One or Two Additional Doses of Licensed Inactivated Polio Vaccines (IPVs) in Latin American Infants Previously Vaccinated With Bivalent Oral Polio Vaccines (bOPVs) Completed NCT01831050 Phase 4
14 A Phase 4, Randomized Trial to Assess the Safety and Immunogenicity of Inactivated Poliovirus Vaccine When Given Concomitantly With Measles and Rubella Combined Vaccine and Yellow Fever Vaccine at Nine Months and When Administered Via Different Vaccination Routes Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
15 Supplementation With Zinc and/or Probiotics to Enhance the Immune Response of Oral Rotavirus and Polio Vaccines in Indian Infants Completed NCT01616693 Phase 4
16 Immunogenicity of Combined Bivalent OPV and IPV Vaccines at 9 - 12 Months of Age Compared to bOPV Alone in Malnourished and Non-Malnourished Pakistani Infants. Completed NCT01695798 Phase 4
17 Cross-sectional Study to Assess Persistence of Immunity Conferred by a Single IPV Dose Administered in the Expanded Program on Immunization(EPI) Routine Immunization Schedule Completed NCT03723837 Phase 4
18 Assessing the Intestinal and Humoral Immunity of Sequential Schedules of Inactivated Poliovirus Vaccine and Bivalent Oral Poliovirus Vaccine for Routine Childhood Immunization in Bangladesh Completed NCT02412514 Phase 4
19 Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIM™) Given as a Booster Dose at 4 to 6 Years of Life in Children Previously Vaccinated With PENTAXIM™ in the Study E2I34 Completed NCT01031303 Phase 4
20 A Phase 4 Study to Evaluate the Safety and Immunogenicity of Monovalent Oral Polio Vaccine Type 2 in Healthy Children Aged 1 to 5 Years and in bOPV-IPV Vaccinated Healthy Infants Completed NCT02521974 Phase 4
21 Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexa™) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
22 A Randomised Controlled Trial Comparing Two-Dose Priming With the 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks to 6 and 14 Weeks in Nepali Children Completed NCT02385513 Phase 4
23 Evaluation of GSK Biological's dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting. Completed NCT00635128 Phase 4
24 A Phase IV (Not Interventional), Open-label, Multicentre Study to Evaluate the Reactogenicity and Safety of Co-administration of GlaxoSmithKline Biologicals' DTPa (Infanrix) and IPV (Poliorix) Vaccines Administered as Three-dose Primary Immunisation Course at 3, 4.5 and 6 Months of Age in Healthy Children in Russian Federation Completed NCT01094171 Phase 4
25 Immunogenicity of a Booster Dose of Fractional Inactivated Poliovirus Vaccine (fIPV) Delivered Intradermally Concomitantly With Rotavirus Vaccines Completed NCT02847026 Phase 4
26 Regulatory Post-Marketing Surveillance (PMS) Study for TETRAXIM™(Combined Vaccine of Adsorbed Diphtheria, Tetanus, Acellular Pertussis and Enhanced Inactivated Poliomyelitis) Completed NCT01437423 Phase 4
27 Immunogenicity and Reactogenicity Study of a New Formulation of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children Completed NCT00611559 Phase 4
28 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
29 Consistency Study for Three Commercial Lots of Inactivated Poliomyelitis Vaccine Made From Sabin Strain Completed NCT04224519 Phase 4
30 Phase IV Safety Monitoring Study of Inactivated Poliomyelitis Vaccine Made From Sabin Strain Completed NCT04220515 Phase 4
31 Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants Completed NCT03147560 Phase 4
32 The Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR) Completed NCT01129284 Phase 4 ACTHAR gel
33 Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Infanrix Hexa™ (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02853929 Phase 4
34 Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses of BIKEN Acellular Pertussis Vaccine in Combination With Diphtheria and Tetanus Toxoids (TRIPEDIA®) or Who Have Received Primary Vaccination With 3 Doses of Whole-Cell Pertussis Vaccine, Plus at Least 1 Pertussis Booster Vaccination Completed NCT00304265 Phase 4
35 Randomised Study of the Impact of Different Doses of Vitamin A on Childhood Morbidity and Mortality Completed NCT00168584 Phase 4 Vitamin A
36 Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Infanrix Hexa Vaccine in Healthy Infants Completed NCT00753649 Phase 4
37 Antibody Persistence in Children Previously Vaccinated With Three Doses of Infanrix Hexa™ or Infanrix-IPV/Hib™ Completed NCT01358825 Phase 4
38 Study to Assess and Compare the Immunogenicity and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA) and Aventis Pasteur MSD's DTPa-HBV-IPV-Hib Vaccine (HEXAVAC™) Given at 3, 5 and 11-12 Months of Age Completed NCT01457547 Phase 4
39 Assessment of the Immunogenicity of Three Doses of Bivalent, Trivalent or Type One Monovalent Oral Poliovirus Vaccines Provided at 2 or 4 Week Intervals Completed NCT01633216 Phase 4
40 An Open, Multicentric, Post-marketing Surveillance Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 and 18 Months of Age, in Healthy Infants. Completed NCT00325156 Phase 4
41 Post-marketing, Randomized, Open-label Study to Assess the Immunogenicity and Safety of Concomitant Administration of V260 and Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Japanese Healthy Infants Completed NCT01926015 Phase 4
42 Immunogenicity and Safety Profile of Primary Dose of Bivalent OPV (bOPV Bio Farma) Given Simultaneously With Pentabio® And Inactivated Poliovirus Vaccine (IPV) at the 4th Visit in Indonesian Infants Completed NCT03310073 Phase 4
43 A Randomized, Multi-center, Controlled Clinical Trial for Evaluating the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV Completed NCT04054492 Phase 4
44 Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Completed NCT00254917 Phase 4
45 Safety of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM®) Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China Completed NCT01491087 Phase 4
46 An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age. Completed NCT01659996 Phase 4
47 A Randomised Controlled Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants Completed NCT02145624 Phase 4 Repevax;Boostrix-IPV
48 Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study Completed NCT02542462 Phase 4 Rotarix®,;Rotarix®, with other routine vaccines;RotaTeq®,;RotaTeq®, with other routine vaccines
49 Trial of Two-Dose Standard Measles Vaccination Schedule: Long-Term Impact on Morbidity and Mortality of a Two-Dose Vaccination Schedule at 6 and 9 Months of Age Compared With a Standard Regimen of One Dose at 9 Months of Age Completed NCT00168662 Phase 4
50 A Phase IV, Randomized Study to Evaluate the Immune Response of UK Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life Completed NCT00625677 Phase 4

Search NIH Clinical Center for Poliomyelitis

Cochrane evidence based reviews: poliomyelitis

Genetic Tests for Poliomyelitis

Anatomical Context for Poliomyelitis

MalaCards organs/tissues related to Poliomyelitis:

40
Testes, Spinal Cord, Brain, Bone, Kidney, Lung, Skin

Publications for Poliomyelitis

Articles related to Poliomyelitis:

(show top 50) (show all 20352)
# Title Authors PMID Year
1
Stable isotope labeling by amino acids in cell culture and differential plasma membrane proteome quantitation identify new substrates for the MARCH9 transmembrane E3 ligase. 54 61
19457934 2009
2
Novel BTK mutation presenting with vaccine-associated paralytic poliomyelitis. 61 54
18317803 2008
3
Evidence for emergence of diverse polioviruses from C-cluster coxsackie A viruses and implications for global poliovirus eradication. 54 61
17517601 2007
4
Feasibility study to develop a common in vitro D antigen assay for inactivated poliomyelitis vaccines. 54 61
16336935 2005
5
A poliomyelitis model through mucosal infection in transgenic mice bearing human poliovirus receptor, TgPVR21. 54 61
15033568 2004
6
Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact. 61 54
14654644 2003
7
Tissue-specific replicating capacity of a chimeric poliovirus that carries the internal ribosome entry site of hepatitis C virus in a new mouse model transgenic for the human poliovirus receptor. 61 54
12970433 2003
8
Establishment of European Pharmacopoeia BRP batch 2 for inactivated poliomyelitis vaccine for in vitro D antigen assay. 54 61
14563307 2003
9
The neuropathology observed in wild-type mice inoculated with human poliovirus mirrors human paralytic poliomyelitis. 61 54
12220986 2002
10
Recent insights into poliovirus pathogenesis. 61 54
11597452 2001
11
Identification of a nuclear respiratory factor-1 binding site within the core promoter of the human polio virus receptor/CD155 gene. 61 54
10777530 2000
12
Expression of the poliovirus receptor in intestinal epithelial cells is not sufficient to permit poliovirus replication in the mouse gut. 61 54
9188553 1997
13
Inactivated poliovirus vaccine protects transgenic poliovirus receptor mice against type 3 poliovirus challenge. 61 54
9203668 1997
14
Identification of two determinants that attenuate vaccine-related type 2 poliovirus. 54 61
1847458 1991
15
Prior poliomyelitis-reduced capillary supply and metabolic enzyme content in hypertrophic slow-twitch (type I) muscle fibres. 54 61
2030351 1991
16
Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. 54 61
2170026 1990
17
Coverage rates of the children vaccination programme in Greenland. 61
32000619 2020
18
Emerging vaccine manufacturers are innovating for the next decade. 61
32462140 2020
19
Immunity and field efficacy of type 2-containing polio vaccines after cessation of trivalent oral polio vaccine: A population-based serological study in Pakistan. 61
32462141 2020
20
Were there long-term economic effects of exposure to polio vaccination? An analysis of migrants to Sweden 1946-2003. 61
32577493 2020
21
A game-theoretical analysis of poliomyelitis vaccination. 61
32371008 2020
22
Childhood infections, vaccinations, and tonsillectomy and risk of first clinical diagnosis of CNS demyelination in the Ausimmune Study. 61
32305688 2020
23
Eradication of persistent coxsackievirus B infection from a pancreatic cell line with clinically used antiviral drugs. 61
32450550 2020
24
Bio-redox potential of Hyphaene thebaica in bio-fabrication of ultrafine maghemite phase iron oxide nanoparticles (Fe2O3 NPs) for therapeutic applications. 61
32409045 2020
25
Prosocial polio vaccination in Israel. 61
32457142 2020
26
The future of vaccine development. 61
31443989 2020
27
Factors affecting the successful implementation of Global Polio Eradication Initiative (GPEI) in low- and middle-income countries. 61
32274015 2020
28
Self-reported impairments among people with late effects of polio: a Mixed-methods study. 61
32556343 2020
29
The use of next generation sequencing for the quality control of live-attenuated polio vaccines. 61
32492703 2020
30
Polio Elimination in North-West Pakistan Faces Setbacks in War-Affected Areas. 61
32500720 2020
31
Underperformed and Underreported Testing for Persistent Oropharyngeal Poliovirus Infections in Primary Immune Deficient Patients-Risk for Reemergence of Polioviruses. 61
32538431 2020
32
Two decades of vaccine innovations for global public good: Report of the Developing Countries' Vaccine Manufacturers Network 20th meeting, 21-23 october 2019, Rio de Janeiro, Brazil. 61
32535016 2020
33
Estimating population immunity to poliovirus in Lebanon: Results from a seroprevalence survey, 2016. 61
32499065 2020
34
Childhood acute disseminated encephalomyelitis: an Egyptian pilot study. 61
29222716 2020
35
Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial. 61
32563609 2020
36
Management Options and Outcomes for Patients with Femoral Fractures with Post-Polio Syndrome of the Lower Extremity: A Critical Analysis Review. 61
32487976 2020
37
Low vaccination in rural Sindh, Pakistan: A case of refusal, ignorance or access? 61
32467011 2020
38
Coverage and Timeliness of Birth Dose Vaccination in Sub-Saharan Africa: A Systematic Review and Meta-Analysis. 61
32545322 2020
39
Prepare for Post-COVID-Pandemic Polio Problems. 61
32393679 2020
40
Control of vaccine preventable diseases in Australian infants: reviewing a decade of experience with DTPa-HBV-IPV/Hib vaccine. 61
32573398 2020
41
Timeliness of childhood vaccinations in Armenia, 2015-2016. 61
32448619 2020
42
Post-Polio Syndrome Causing Late Onset Respiratory Failure. 61
32558449 2020
43
Impact of a Catch-Up Strategy of DT-IPV Vaccination during Hospitalization on Vaccination Coverage among People Over 65 Years of Age in France: The HOSPIVAC Study (Vaccination during Hospitalization). 61
32527049 2020
44
Persistent pruritic subcutaneous nodules at injection sites and other delayed type hypersensitivity reactions to aluminium adsorbed vaccines in Irish children: a case series. 61
32506521 2020
45
Movement Analysis in Orthopedics and Trauma Surgery - Measurement Systems and Clinical Applications. 61
31291674 2020
46
Development of broad-spectrum enterovirus antivirals based on quinoline scaffold. 61
32559580 2020
47
Biennial Upsurge and Molecular Epidemiology of Enterovirus D68 Infection in New York, United States, 2014-2018. 61
32493783 2020
48
Serostatus following polio-containing vaccination before and after liver transplantation. 61
32558028 2020
49
THE RISK OF BONE FRACTURES IN POST-POLIOMYELITIS PATIENTS TRANSITIONING TO MIDDLE ADULTHOOD. 61
32576037 2020
50
COVID-19 and Laparoscopic Surgery: Scoping Review of Current Literature and Local Expertise. 61
32406853 2020

Variations for Poliomyelitis

Expression for Poliomyelitis

Search GEO for disease gene expression data for Poliomyelitis.

Pathways for Poliomyelitis

Pathways related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 TNF RASA3 PVR IL4 IL10 IFNG
2
Show member pathways
13.31 TNF RASA3 IL4 IL10 IFNG ICAM1
3
Show member pathways
12.82 TNF IL4 IL10 IFNG ICAM1 CD40LG
4
Show member pathways
12.6 TNF IL4 IL10 IFNG CD40LG BTK
5
Show member pathways
12.56 TNF IL4 IL10 IFNG DLG1 CD40LG
6
Show member pathways
12.46 TNF IL4 IFNG ICAM1 FCGR3B FCGR3A
7 12.38 TNF PVR IL4 IL10 IFNG CD40LG
8
Show member pathways
12.28 TNF IL4 IFNG ICAM1
9 12.1 TNF IL10 IFNG FCGR3B FCGR3A FCGR2A
10 12.06 PVR ICAM1 FCGR3A CD40LG
11 11.96 TNF IL4 IL10 ICAM1
12 11.94 TNF IL4 IL10 IFNG FCGR2A
13 11.91 TNF ICAM1 CD40LG BTK
14 11.84 TNF IFNG FCGR3B FCGR3A FCGR2A BTK
15 11.81 IL10 ICAM1 FCGR3B FCGR3A FCGR2A
16 11.76 TNF IL4 IL10 IFNG
17 11.75 IL4 IFNG ICAM1
18
Show member pathways
11.73 TNF IL4 IFNG CD40LG
19 11.7 TNF IL10 IFNG
20 11.62 IL4 IL10 CD40LG
21
Show member pathways
11.62 TNF IFNG ICAM1 CD40LG
22 11.51 TNF LEP IL4 IFNG ICAM1 FCGR2A
23
Show member pathways
11.5 TNF IL4 IL10 IFNG FCGR3B FCGR3A
24 11.49 TNF IL4 IL10 ICAM1
25 11.48 IL4 IL10 IFNG
26
Show member pathways
11.36 TNF IL10 IFNG
27 11.33 TNF IL10 IFNG ICAM1
28 11.31 IL4 IFNG CD40LG
29 11.29 TNF IL4 IFNG
30 11.25 TNF IL10 IFNG ICAM1 CD40LG
31 11.17 IL4 IL10 IFNG
32 11.17 TNF IL4 IL10 IFNG
33 11 TNF IL4 IL10 CD40LG BTK ARHGEF1

GO Terms for Poliomyelitis

Cellular components related to Poliomyelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 TNF PVR LEP IL4 IL10 IFNG
2 plasma membrane GO:0005886 9.77 TNF SCARB2 RASA3 PVR ICAM1 FCGR3B
3 membrane raft GO:0045121 9.46 TNF ICAM1 DLG1 BTK
4 extracellular region GO:0005576 9.32 TNF PVR LEP IL4 IL10 IFNG

Biological processes related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.87 TNF ICAM1 CD40LG BTK
2 viral entry into host cell GO:0046718 9.84 SCARB2 PVR ICAM1
3 B cell differentiation GO:0030183 9.83 IL4 IL10 CD40LG
4 response to insulin GO:0032868 9.83 LEP IL10 ICAM1
5 regulation of insulin secretion GO:0050796 9.82 TNF LEP IFNG
6 positive regulation of T cell proliferation GO:0042102 9.8 LEP IL4 CD40LG
7 positive regulation of protein localization to plasma membrane GO:1903078 9.8 TNF IFNG DLG1
8 positive regulation of nitric oxide biosynthetic process GO:0045429 9.73 TNF IFNG ICAM1
9 negative regulation of endothelial cell apoptotic process GO:2000352 9.71 IL4 IL10 ICAM1
10 negative regulation of mitotic cell cycle GO:0045930 9.7 TNF IL10 DLG1
11 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.66 IL4 IL10
12 negative regulation of amyloid-beta clearance GO:1900222 9.65 TNF IFNG
13 negative regulation of lipid storage GO:0010888 9.65 TNF LEP
14 positive regulation of cytokine secretion GO:0050715 9.65 TNF IL10 IFNG
15 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.64 TNF IFNG
16 endothelial cell apoptotic process GO:0072577 9.63 TNF IL10
17 positive regulation of JAK-STAT cascade GO:0046427 9.63 TNF LEP IL10
18 positive regulation of mononuclear cell migration GO:0071677 9.62 TNF IL4
19 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.62 TNF LEP IL4 IFNG
20 type 2 immune response GO:0042092 9.61 IL4 IL10
21 negative regulation of cytokine production involved in immune response GO:0002719 9.61 TNF IL10
22 microglial cell activation GO:0001774 9.61 TNF IL4 IFNG
23 positive regulation of cellular respiration GO:1901857 9.6 IL4 IFNG
24 neuroinflammatory response GO:0150076 9.59 IL4 IFNG
25 regulation of immunoglobulin secretion GO:0051023 9.58 TNF CD40LG
26 negative regulation of cytokine secretion involved in immune response GO:0002740 9.58 TNF IL10
27 regulation of isotype switching GO:0045191 9.55 IL4 IL10
28 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.51 TNF IFNG
29 immune response GO:0006955 9.5 TNF IL4 IL10 IFNG FCGR3B FCGR3A
30 receptor biosynthetic process GO:0032800 9.49 TNF IL10
31 positive regulation of chemokine biosynthetic process GO:0045080 9.43 TNF IL4 IFNG
32 positive regulation of vitamin D biosynthetic process GO:0060557 9.4 TNF IFNG
33 positive regulation of nitrogen compound metabolic process GO:0051173 9.37 TNF IFNG
34 positive regulation of MHC class II biosynthetic process GO:0045348 9.33 IL4 IL10 IFNG
35 regulation of immune response GO:0050776 9.17 PVR IL4 ICAM1 FCGR3B FCGR3A FCGR2A

Molecular functions related to Poliomyelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 9.55 SCARB2 ICAM1 FCGR3B FCGR3A FCGR2A
2 virus receptor activity GO:0001618 9.43 SCARB2 PVR ICAM1
3 cytokine activity GO:0005125 9.35 TNF IL4 IL10 IFNG CD40LG
4 IgG binding GO:0019864 8.8 FCGR3B FCGR3A FCGR2A

Sources for Poliomyelitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....